PARP1 and cancer: Going forward, this model could be used to investigate the in vivo consequences of PARP1 inhibition in the absence of BRCA2 either genetically or pharmacologically, as well as screen for compounds or genes that could restore HR in the absence of BRCA2, thereby providing insights into resistance mechanisms that need to be considered during treatment of these cancers.